Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosfomycin vs ciprofloxacin for febrile neutropenia prophylaxis in hematologic patients
2021-000354-25Phase 3Active
- Sponsor
- FINBA
- Start
- Aug 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in neutropenia, febrile neutropenia (FN), Acute Leukaemia and 1 more comparing Oral fosfomycin prophylaxis with Oral ciprofloxacin prophylaxis (2 arms). Primary endpoint: Efficacy non-inferiority for prevention of febrile neutropenia. Started Aug 2021; status: active.
02
Drugs
fosfomycinciprofloxacin
03
Conditions
neutropeniafebrile neutropenia (FN)Acute Leukaemiastem cell transplant (SCT)
Beyond the preview
Go deeper on 2021-000354-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000354-25.